Clinical assessment of immune-related adverse events

Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosa, Aaron, Lopez Cadena, Esther, Simon Olive, Cristina, Karachaliou, Niki, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882039/
https://www.ncbi.nlm.nih.gov/pubmed/29623110
http://dx.doi.org/10.1177/1758835918764628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882039/
https://www.ncbi.nlm.nih.gov/pubmed/29623110
http://dx.doi.org/10.1177/1758835918764628

Ejemplares similares